This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic ...

Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for ...

PLEASANTON, Calif., July 30, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® prime Pre-analytical System to improve efficiency in molecular diagnostics ...

Basel, 17 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of cobas pure integrated solutions in countries accepting the CE mark.3 This new compact analyser combines three ...

First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals Basel, 12 January 2022 - ...

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour ...

Molecular laboratories are seeking to automate, standardise and connect molecular testing as much as possible in order to address increasing testing demand. The cobas prime Pre-analytical System ...

Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of care settings First diagnostic solution at the point of care to serve as a ...

Roche announced the launch of the cobas pulse system in select countries accepting the CE Mark. The cobas pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions ...